

Ref: STEX/INTIMATION/2025-26

Date: August 07, 2025

BSE Limited

Department of Corporate Services-Listing
PJ Towers, Dalal Street
Mumbai- 400001

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex
Bandra (E) Mumbai- 400051

Scrip Code- 531146

Symbol- MEDICAMEQ

Subject: Intimation under SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

Pursuant to Regulation 29 read with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that a Meeting of the Board of Directors of Medicamen Biotech Limited ('the Company') is scheduled to be held on Tuesday, August 12, 2025 at the registered office of the Company situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 to inter-alia, consider and approve the following business(s):

1. To consider, approve and take on records of Un-audited financial results (Standalone & Consolidated) for quarter ended on June 30, 2025
2. To consider & approve draft Annual Report for the financial year 2024-25.
3. To consider and approve draft Cost Audit report for the financial year 2024-25.
4. To consider and approve appointment of Mr. Ashwani Kumar Sharma (DIN: 00325634) as Whole-time Director to be designated as Executive Director of the Company for a period of five years subject to the approval of shareholders in the ensuing General Meeting of the Company.
5. To consider and approve appointment of Mr. Sham Goel (DIN: 02183287) as Non-Executive Independent Director of the Company subject to the approval of shareholders in the ensuing General Meeting of the Company.
6. To consider and approve appointment of Mr. Shaival Saurabh (DIN: 01971944) as Non-Executive Independent Director of the Company subject to the approval of shareholders in the ensuing General Meeting of the Company.
7. Any other business with the permission of the chair.

It was informed that pursuant to the Company's Code of Conduct framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and amendments made there under, the trading window for dealing in the shares of the Company is closed for all designated persons of the Company from the July 01, 2025 and will open 48 hours after the said Financial Results are declared to Stock Exchanges.

This is for your information and record.

Yours faithfully

For Medicamen Biotech Limited

Parul Choudhary
Company Secretary & Compliance Officer
ACS: 44157